



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tigatuzumab

Cat. No.:	HY-P99270
CAS No.:	918127-53-4
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer ^[1] .									
In Vitro	<p>Tigatuzumab is sensitive to MIA PaCa-2 cells and BxPC-3 cells with IC₅₀ values of 2.95 and 8.21 µg/mL, respectively^[1]. Tigatuzumab (3-8 µg/mL; 5 h) induces apoptosis of cancer cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MIA PaCa-2 and BxPC-3 cell lines</td> </tr> <tr> <td>Concentration:</td> <td>3 and 8 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>5 hours</td> </tr> <tr> <td>Result:</td> <td>Induced cell apoptosis, and the methionine restriction increased the caspase activation and apoptosis in pancreatic cancer cells.</td> </tr> </table>		Cell Line:	MIA PaCa-2 and BxPC-3 cell lines	Concentration:	3 and 8 µg/mL	Incubation Time:	5 hours	Result:	Induced cell apoptosis, and the methionine restriction increased the caspase activation and apoptosis in pancreatic cancer cells.
Cell Line:	MIA PaCa-2 and BxPC-3 cell lines									
Concentration:	3 and 8 µg/mL									
Incubation Time:	5 hours									
Result:	Induced cell apoptosis, and the methionine restriction increased the caspase activation and apoptosis in pancreatic cancer cells.									
In Vivo	<p>Tigatuzumab (3 mg/kg; i.v. weekly for 4 weeks) effectively represses the tumor growth in human pancreatic cancer MIA PaCa-2-RFP orthotopic mouse model^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection^[1]</td> </tr> <tr> <td>Dosage:</td> <td>3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; 3 mg/kg weekly for 4 weeks</td> </tr> <tr> <td>Result:</td> <td>Reduced the tumor volume and decreased the density of viable cancer cells in tumors.</td> </tr> </table>		Animal Model:	Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection ^[1]	Dosage:	3 mg/kg	Administration:	Intravenous injection; 3 mg/kg weekly for 4 weeks	Result:	Reduced the tumor volume and decreased the density of viable cancer cells in tumors.
Animal Model:	Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection ^[1]									
Dosage:	3 mg/kg									
Administration:	Intravenous injection; 3 mg/kg weekly for 4 weeks									
Result:	Reduced the tumor volume and decreased the density of viable cancer cells in tumors.									

REFERENCES

[1]. Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA